<PAPER><mode2 name='PMC4691687' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:ali='http://www.niso.org/schemas/ali/1.0' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Neurology</journal-id><journal-id journal-id-type='iso-abbrev'>Neurology</journal-id><journal-id journal-id-type='hwp'>neurology</journal-id><journal-id journal-id-type='publisher-id'>neur</journal-id><journal-id journal-id-type='pmc'>neurology</journal-id><journal-id journal-id-type='publisher-id'>NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type='ppub'>0028-3878</issn><issn pub-type='epub'>1526-632X</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4691687</article-id><article-id pub-id-type='pmid'>26581300</article-id><article-id pub-id-type='publisher-id'>NEUROLOGY2015667717</article-id><article-id pub-id-type='doi'>10.1212/WNL.0000000000002220</article-id><article-categories><subj-group subj-group-type='hwp-journal-coll'><subject>29</subject><subject>54</subject><subject>91</subject></subj-group><subj-group subj-group-type='heading'><subject>Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Loss of <italic>TBK1</italic> is a frequent cause of frontotemporal dementia in a Belgian cohort</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Gijselinck</surname><given-names>Ilse</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>(1) The Research Foundation - Flanders (FWO), PI, 2012-2015</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>(1) Queen Elisabeth Medical Foundation (QEMF), (2) Alzheimer Research Foundation (SAO-FRA)</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Van Mossevelde</surname><given-names>Sara</given-names></name><degrees>MD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>van der Zee</surname><given-names>Julie</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Sieben</surname><given-names>Anne</given-names></name><degrees>MD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Philtjens</surname><given-names>Stéphanie</given-names></name><degrees>MSc</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>(1) The Research Foundation - Flanders (FWO), 11E9614N, FWO aspirant (PhD), 2013-2015</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Heeman</surname><given-names>Bavo</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Engelborghs</surname><given-names>Sebastiaan</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>Memberships of advisory boards: Innogenetics / Fujirebio Europe, Novartis, UCB, Roche diagnostics, Nutricia / Danone</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>Senior Editor, Journal of Alzheimer's Disease; Member of the editorial advisory board of Clinical Neurology and Neurosurgery</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>Janssen Pharmaceutica NV</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>Several grants from the Research Foundation Flanders (FWO-Vlaanderen) and the Agency for Innovation by Science and Technology(IWT)</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>Several grants from the Special Research Fund (BOF) of the University of Antwerp</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>Several grants from the Alzheimer Research Foundation (SAO- FRA)</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Vandenbulcke</surname><given-names>Mathieu</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>De Baets</surname><given-names>Greet</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Bäumer</surname><given-names>Veerle</given-names></name><degrees>BSc</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>1) The research foundation - Flanders (FWO), PI 2014-2017, 2) Belgian science policy office (BELSPO), Interuniversity Attraction Poles (IAP) Key Person, 2012-2017</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>1) Queen Elisabeth Medical Foundation (QEMF), 2) Alzheimer Research Foundation (SAO-FRA)</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Cuijt</surname><given-names>Ivy</given-names></name><degrees>MSc</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Van den Broeck</surname><given-names>Marleen</given-names></name><degrees>BSc</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Peeters</surname><given-names>Karin</given-names></name><degrees>BSc</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Mattheijssens</surname><given-names>Maria</given-names></name><degrees>BSc</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Rousseau</surname><given-names>Frederic</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>(1) Scientific Advisory Board Member, Stichting Alzheimer Onderzoek Belgium</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>Editorial Board Member Protein Engineering, Design &amp; Selection (PEDS)</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>? EP 13169476.2;Priority date: 28/05/2013; Title: Single domain antibodies against SOD1 and their use in medicine Joost Schymkowitz, Frederic Rousseau, Wim Robberecht ? WO 2013/156552; Priority date: 18/04/2012; Title: Means and methods for generating improved proteins Joost Schymkowitz &amp; Frederic Rousseau ? WO 2012/130785; Priority date: 25/03/2011: Title: Screening molecules interfering with aggregation of tumor suppressor proteins, compounds derived thereof and their use for treating cancer Jie Xu, Frederik De Smet, Joost Schymkowitz, Frederic Rousseau ? WO 2012/123419; Priority date: 11/03/2011; Title: Molecules and methods for inhibiting and detection of proteins Joost Schymkowitz, Frederic Rousseau ? WO 2011/001413; Priority date: 03/07/2009; Title: Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor C. Herbert, Frederic Rousseau, Frederik De Smet, Joost Schymkowitz, Peter Carmeliet ? PCT/EP2008/056842; Priority date: 04/06/2007: Title: Means and methods for inducing fibrillar aggregation Frederic Rousseau, Joost Schymkowitz ? WO 2008/148751; Priority date: 04/06/2007; Title: Means and methods for inducing protein aggregation Frederic Rousseau, Joost Schymkowitz ? WO 2008/028939; Priority date: 08/09/2006; Title: Means and methods for the production of amyloid oligomers Bart De Strooper, Frederic Rousseau, Ivo da Rocha Martins, Joost Schymkowitz ? WO 2007/071789; Priority date: 22/12/2005; Title: Means and methods for mediating protein interference Frederic Rousseau, Joost Schymkowitz Thus far granted in Australia, Europe &amp; Israel.</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>(1) Mechanism of drug resistance in wild-type expression p53 tumours FWO (G.0829.13N) (2) Neurobrainnet network IAP/BELSPO (P7/16)</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>(1) Frederic Rousseau Clinical impact of protein aggregation in cancer OT/12/092, University of Leuven</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Vandenberghe</surname><given-names>Rik</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>GE Healthcare scientific advisory board</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>(1) GE Healthcare (2) Novartis</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>BelSpo P7/11, partner, 2012-2017 Flemish Research Foundation senior clinical investigator fellowship Flemish Research Foundation grant G0925.15N and G0A09.13N (PI) IWT VIND (coordinator) IWT BioAdaptAD (coordinator)</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>KU Leuven OT/12/097 PI 2013-2016</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>Stichting Alzheimer Onderzoek #13007</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>De Jonghe</surname><given-names>Peter</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>(1) Acta Neurologica Belgica; editorial advisory board; 2009-</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>Fund for Scientific Research, International Coordination Action;</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>Geneeskundige Stichting Koningin Elisabeth (GSKE)</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Cras</surname><given-names>Patrick</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>De Deyn</surname><given-names>Peter P.</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>Clinical Neurology and Neurosurgery, Editor In Chief since 13 years</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>Animal Models of Dementia, Springer, 2011</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Martin</surname><given-names>Jean-Jacques</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>Editorial Advisory Board Member Clinical Neurology and Neurosurgery Elsevier Editorial Advisory Board Member Clinical Neuropathology Dustri verlag</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author' corresp='yes'><name><surname>Cruts</surname><given-names>Marc</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>(1) The Research Foundation ? Flanders (FWO), PI, 2014-2017, (2) Belgian Science Policy Office (BELSPO) - Interuniversity Attraction Poles (IAP), Key Person, 2012-2017</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>(1) Queen Elisabeth Medical Foundation (QEMF), (2) Alzheimer Research Foundation (SAO-FRA)</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author' corresp='yes'><name><surname>Van Broeckhoven</surname><given-names>Christine</given-names></name><degrees>DSc</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>Associate Editor Genes, Brain and Behavior Associate Editor NeuroMolecular Medicine Communicating Editor, Human Mutation Member of the Editorial Board of the NEJM</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>University of Antwerp, salary as tenured full professor</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>VIB, Competitive Research Funding</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><on-behalf-of>On behalf of the BELNEU Consortium</on-behalf-of><aff>From the Department of Molecular Genetics (I.G., S.V.M., J.v.d.Z., A.S., S.P., B.H., V.B., I.C., M.V.d.B., K.P., M.M., P.D.J., M.C., C.V.B.), VIB, Antwerp; Institute Born-Bunge (I.G., S.V.M., J.v.d.Z., A.S., S.P., B.H., S.E., V.B., I.C., M.V.d.B., K.P., M.M., P.D.J., P.C., P.P.D.D., J.-J.M., M.C., C.V.B.), University of Antwerp; the Department of Neurology (A.S.), University Hospital Ghent and University of Ghent; the Department of Neurology and Memory Clinic (S.E., P.P.D.D.), Hospital Network Antwerp Middelheim and Hoge Beuken; the Brain and Emotion Laboratory, Department of Psychiatry (M.V.), SWITCH Laboratory, VIB (G.D.B., F.R.), and Laboratory for Cognitive Neurology, Department of Neurology (R.V.), University of Leuven; the Department of Neurology (M.V., R.V.), University Hospitals Leuven, Gasthuisberg; and the Department of Neurology (P.D.J., P.C.), Antwerp University Hospital, Edegem, Belgium. P.P.D.D. is also affiliated with the Department of Neurology and Alzheimer Research Center, University of Groningen and University Medical Center Groningen, the Netherlands.</aff></contrib-group><contrib-group><contrib contrib-type='collab'><collab>BELNEU Consortium</collab></contrib><contrib contrib-type='collab'><name><surname>Nuytten</surname><given-names>Dirk</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type='collab'><name><surname>Van Langenhove</surname><given-names>Tim</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Smets</surname><given-names>Katrien</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Baets</surname><given-names>Jonathan</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Robberecht</surname><given-names>Wim</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Van Damme</surname><given-names>Philip</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>De Bleecker</surname><given-names>Jan</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type='collab'><name><surname>Santens</surname><given-names>Patrick</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Dermaut</surname><given-names>Bart</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Deryck</surname><given-names>Olivier</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type='collab'><name><surname>Bergmans</surname><given-names>Bruno</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Delbeck</surname><given-names>Jean</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type='collab'><name><surname>Versijpt</surname><given-names>Jan</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Michotte</surname><given-names>Alex</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Willems</surname><given-names>Christiana</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type='collab'><name><surname>Ivanoiu</surname><given-names>Adrian</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type='collab'><name><surname>Salmon</surname><given-names>Eric</given-names></name><degrees>MD PhD</degrees></contrib></contrib-group><author-notes><corresp>Correspondence to Dr. Van Broeckhoven: <email>christine.vanbroeckhoven@molgen.vib-ua.be</email> or Dr. Cruts: <email>marc.cruts@molgen.vib-ua.be</email></corresp><fn fn-type='other'><p>Belgium Neurology (BELNEU) consortium members are listed on the <italic>Neurology</italic>® Web site at <ext-link ext-link-type='uri' xlink:href='http://neurology.org/lookup/doi/10.1212/WNL.0000000000002220'>Neurology.org</ext-link>.</p></fn><fn fn-type='financial-disclosure'><p>Go to <ext-link ext-link-type='uri' xlink:href='http://neurology.org/lookup/doi/10.1212/WNL.0000000000002220'>Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the Flanders Impulse Program on Networks for Dementia Research (VIND).</p></fn></author-notes><pub-date pub-type='ppub'><day>15</day><month>12</month><year>2015</year></pub-date><pub-date pub-type='pmc-release'><day>15</day><month>12</month><year>2015</year></pub-date><volume>85</volume><issue>24</issue><fpage>2116</fpage><lpage>2125</lpage><history><date date-type='received'><day>19</day><month>5</month><year>2015</year></date><date date-type='accepted'><day>18</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>© 2015 American Academy of Neurology</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type='open-access'><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by-nc-nd/4.0/'>Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p></license></permissions><self-uri xlink:type='simple' xlink:title='pdf' xlink:href='NEUROLOGY2015667717.pdf'></self-uri><abstract><sec><title>Objective:</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>To assess the genetic contribution of <italic>TBK1</italic>, a gene implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and FTD-ALS, in Belgian FTD and ALS patient cohorts containing a significant part of genetically unresolved patients.</s></p></sec><sec><title>Methods:</title><p><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc2>We sequenced <italic>TBK1</italic> in a hospital-based cohort of 482 unrelated patients with FTD and FTD-ALS and 147 patients with ALS and an extended Belgian FTD-ALS family DR158.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We followed up mutation carriers by segregation studies, transcript and protein expression analysis, and immunohistochemistry.</s></p></sec><sec><title>Results:</title><p><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>We identified 11 patients carrying a loss-of-function (LOF) mutation resulting in an overall mutation frequency of 1.7% (11/629), 1.1% in patients with FTD (5/460), 3.4% in patients with ALS (5/147), and 4.5% in patients with FTD-ALS (1/22).</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> We found 1 LOF mutation, p.Glu643del, in 6 unrelated patients segregating with disease in family DR158.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Of 2 mutation carriers, brain and spinal cord was characterized by TDP-43-positive pathology.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The LOF mutations including the p.Glu643del mutation led to loss of transcript or protein in blood and brain.</s></p></sec><sec><title>Conclusions:</title><p><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1><italic>TBK1</italic> LOF mutations are the third most frequent cause of clinical FTD in the Belgian clinically based patient cohort, after <italic>C9orf72</italic> and <italic>GRN</italic>, and the second most common cause of clinical ALS after <italic>C9orf72</italic>.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These findings reinforce that FTD and ALS belong to the same disease continuum.</s></p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Frontotemporal lobar degeneration (FTLD) is a heterogeneous neurodegenerative disorder associated with amyotrophic lateral sclerosis (ALS) in approximately 10%–15% of patients with frontotemporal dementia (FTD).<sup><xref rid='R1' ref-type='bibr'>1</xref></sup></s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Evidence that common disease pathways are involved in FTD and ALS stems from the observation of families and individual patients in which both diseases occur (FTD-ALS),<sup><xref rid='R1' ref-type='bibr'>1</xref></sup> and the TDP-43 inclusions in both patient groups.<sup><xref rid='R2' ref-type='bibr'>2</xref></sup></s></p><p><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Nearly 50% of FTD cases and 10% of ALS cases aggregate in families, suggesting a strong genetic component.</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The most convincing genetic evidence for a common pathomechanism is provided by the repeat expansion mutations in <italic>C9orf72</italic> in patients with FTD, ALS, and FTD-ALS.<sup><xref rid='R3' ref-type='bibr'>3</xref><xref rid='R4' ref-type='bibr'>–</xref><xref rid='R5' ref-type='bibr'>5</xref></sup></s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recently, <italic>TBK1</italic> loss-of-function (LOF) mutations were identified in patients with ALS<sup><xref rid='R6' ref-type='bibr'>6</xref>,<xref rid='R7' ref-type='bibr'>7</xref></sup> and FTLD-TDP.<sup><xref rid='R8' ref-type='bibr'>8</xref></sup></s></p><p><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In the Belgian FTD cohort, mutations in known genes accounted for 30% of familial FTD and 75% of familial FTD-ALS, with several families with autosomal dominant inheritance remaining genetically unresolved.<sup><xref rid='R5' ref-type='bibr'>5</xref>,<xref rid='R9' ref-type='bibr'>9</xref></sup></s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Here, we investigated the genetic role of <italic>TBK1</italic> in a Belgian cohort of 629 patients with FTD, FTD-ALS, and ALS.</s></p><sec sec-type='methods' id='s1'><title>METHODS</title><sec id='s1-1'><title>Subjects.</title><p><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Our study population consisted of 482 patients with FTD, 22 of whom had concomitant ALS (FTD-ALS), and 147 patients with ALS ascertained in Belgium through an ongoing multicenter collaboration of neurology departments and memory clinics partnering in the Belgian Neurology (BELNEU) consortium.</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Additional patients were included who had initially been referred to the Diagnostic Service Facility for medical genetic testing.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Patients were diagnosed using a standard protocol and established clinical criteria.<sup><xref rid='R10' ref-type='bibr'>10</xref><xref rid='R11' ref-type='bibr'>–</xref><xref rid='R12' ref-type='bibr'>12</xref></sup></s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Postmortem neuropathologic analysis confirmed diagnosis in 25 patients with FTD, 3 patients with FTD-ALS, and 6 patients with ALS.</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> A positive familial history, i.e., at least one first-degree relative with a FTD-ALS spectrum disease, was recorded in 132 patients with FTD (28.7%), 4 patients with FTD-ALS (36.4%), and 18 patients with ALS (12.2%).</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Of these familial index patients, 93 cases of FTD (70.5%), 1 case of FTD-ALS (25.0%) and 7 cases of ALS (38.9%) were not explained by mutations in the known FTLD and ALS genes (<italic>MAPT</italic>, <italic>GRN</italic>, <italic>C9orf72</italic>, <italic>VCP</italic>, <italic>CHMP2B</italic>, <italic>FUS</italic>, <italic>TARDBP</italic>, <italic>SOD1</italic>), in the AD genes (<italic>PSEN1</italic>, <italic>PSEN2</italic>, <italic>APP</italic>), or in the prion gene (<italic>PRNP</italic>).</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> One patient with unexplained FTD-ALS was the index patient of a 4-generation family (family DR158), of which we collected genomic DNA and generated lymphoblast cell lines of 38 individuals including 4 patients in generation III (<xref rid='F1' ref-type='fig'>figure 1</xref> and <xref rid='T1' ref-type='table'>table 1</xref>).</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> A Belgian control cohort of 1,044 persons free of personal and familial history of neurodegenerative or psychiatric diseases and with a Mini-Mental State Examination score &gt;26 was also analyzed.</s></p><fig id='F1' position='float'><label>Figure 1</label><caption><title>Pedigrees show segregation and disease haplotype sharing in patients and families with the TBK1 mutation p.Glu643del</title><p>To protect the privacy of the participants, we masked the sex of each person, scrambled the pedigree of family DR158, and did not specify the number of at-risk individuals tested shown in the white diamonds. The index patient is indicated with an arrow. Filled symbols represent patients, with their age at onset (AAO) in years below their symbol. Age at death (AAD) is shown for individuals who died in old age without symptoms. In family DR663, 3 of the 4 children also carry a repeat expansion mutation in <italic>C9orf72</italic>, 2 affected (I-1 and II-2) and 1 asymptomatic (II-4), for whom the age at last examination (AALE) is given. An asterisk identifies the family members for whom genomic DNA was available. The Glu643del mutation is shown as “–.” The 5 polymorphic markers, including the TBK1-(GT)<sub>n</sub> repeat polymorphism located 400 kb upstream of <italic>TBK1</italic>, are indicated at the left and flank the <italic>TBK1</italic> mutation p.Glu643del at both sites. Genotypes of additional polymorphic markers can be found in table e-3. The 3 different disease haplotypes are shown with colored bars: green haplotype of at least 7.5 Mb, purple haplotype of at least 8.7 Mb, and orange haplotype of at least 3.0 Mb. Haplotypes based on segregation data are indicated in regular font, those based on allele sharing are in italics, and those that were inferred are between brackets. ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia.</p></caption><graphic xlink:href='NEUROLOGY2015667717FF1'></graphic></fig><table-wrap id='T1' position='float'><label>Table 1</label><caption><p>Clinical characteristics of patients of family DR158 and <italic>TBK1</italic> mutation carriers</p></caption><graphic xlink:href='NEUROLOGY2015667717TT1'></graphic></table-wrap></sec><sec id='s1-2'><title>Standard protocol approvals, registrations, and patient consents.</title><p><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>All participants provided written informed consent for participation in clinical, pathologic, and genetic studies.</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Clinical study protocols and informed consent forms were approved by the local medical ethics committees of the collaborating clinical centers.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Genetics study protocol and informed consent forms were approved by the medical ethics committees of the University Hospital Antwerp and the University of Antwerp.</s></p></sec><sec id='s1-3'><title>Experimental procedures.</title><p><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Nineteen coding <italic>TBK1</italic> exons were amplified in multiplex PCR reactions using MASTR technology (<ext-link ext-link-type='uri' xlink:href='http://www.multiplicom.com/'>http://www.multiplicom.com</ext-link>) and sequenced on a MiSeq platform (Illumina; San Diego, CA) and 1 exon was analyzed by Sanger sequencing.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Identified variants were validated and relatives of mutation carriers were analyzed using Sanger sequencing.</s></p><p><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1><italic>TBK1</italic> transcripts were measured in lymphoblast cells of 8 mutation carriers and frontal cortex of 2 carriers using real-time PCR amplification of a <italic>TBK1</italic>amplicon, quantified against 2 housekeeping genes.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We sequenced real-time PCR products to establish the transcribed alleles based on the coding mutation or the coding polymorphism rs7486100.</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We used western blotting of protein lysates of lymphoblast cells and brain with a monoclonal antibody against TBK1 and quantified against GAPDH.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We performed neuropathologic analysis of brain and spinal cord of 2 <italic>TBK1</italic> mutation carriers.</s></p><p><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Appendix e-1 on the <italic>Neurology</italic>® Web site at <ext-link ext-link-type='uri' xlink:href='http://neurology.org/lookup/doi/10.1212/WNL.0000000000002220'>Neurology.org</ext-link> contains further technical details.</s></p></sec></sec><sec sec-type='results' id='s2'><title>RESULTS</title><sec id='s2-1'><title><italic>TBK1</italic> mutation analysis and the effect on transcript and protein expression.</title><p><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>We screened the coding region of <italic>TBK1</italic> and identified 2 frameshift, 1 nonsense, 1 splice site mutation, and 2 single amino acid deletions in 11 unrelated index patients (<xref rid='T1' ref-type='table'>table 1</xref>, table e-1, and figure e-1).</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Further, we identified 5 missense mutations in 5 patients.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Copy number variation analysis of all <italic>TBK1</italic> exons did not reveal exonic or whole gene deletions or duplications.</s></p><p><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>We predicted that the nonsense and frameshift mutations resulted in a premature termination codon leading to mRNA degradation by nonsense-mediated decay. cDNA sequencing of <italic>TBK1</italic> in lymphoblast cells of the Ser398Profs*11 carrier, and in brain of the p.Ser518Leufs*32 carrier, did not identify the mutant allele, suggesting a complete loss of the mutant transcript.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Quantification of <italic>TBK1</italic> transcripts demonstrated a highly reduced gene expression that was restored to normal levels using an inhibitor of protein synthesis (<xref rid='F2' ref-type='fig'>figure 2</xref>).</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Western blot analysis demonstrated near 50% reduction of protein expression in lymphoblast cells and in brain (<xref rid='F3' ref-type='fig'>figure 3</xref>).</s></p><fig id='F2' position='float'><label>Figure 2</label><caption><title>Transcript analysis of TBK1 loss-of-function mutations</title><p>Quantitative PCR quantification of <italic>TBK1</italic> transcripts from lymphoblast cells (A) and frontal cortex (B) of LOF mutation carriers (blue bars) compared to control persons without mutation (black bars) normalized to different housekeeping genes. Five unrelated p.Glu643del mutation carriers were included. Error bars represent the SD. Below the chart is indicated if cells were treated (+, dark blue bars) or not treated (−, light blue bars) with cycloheximide (CHX), a protein synthesis inhibitor. Sequence traces are obtained by real-time PCR from the lymphoblast cells of the p.Ser398Profs*11 mutation carrier treated or not treated with CHX using primers in exon 6 and exon 21. (C) Real-time PCR with primers in exon 6 and 10 of cDNA of brain of the p.Gly272_Thr331del mutation carriers is shown on agarose gel, with the respective sequence traces from the aberrant transcripts.</p></caption><graphic xlink:href='NEUROLOGY2015667717FF2'></graphic></fig><fig id='F3' position='float'><label>Figure 3</label><caption><title>Protein analysis of TBK1 loss-of-function mutations</title><p>Western blot analysis of protein extracts from lymphoblast cells (A) and frontal cortex (B) of loss-of-function (LOF) mutation carriers compared to control persons without mutation. Of the p.Glu643del mutation, 5 unrelated index patients were included. The upper band represents TBK1 (84 kDa) and the lower band the housekeeping protein GAPDH (37 kDa). The graphs below (C) show the quantification in control samples (black) and patient samples (blue) of the TBK1 signal normalized to the signal of GAPDH. Error bars represent the SD; ** indicates a significant <italic>p</italic> value of &lt;0.01 compared to controls.</p></caption><graphic xlink:href='NEUROLOGY2015667717FF3'></graphic></fig><p><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>In DR189, a mutation affecting the intron 8 splice donor site resulted in in-frame skipping of exon 8 in lymphoblast cells and brain.</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In addition, use of a cryptic splice site in exon 8 resulted in an out-of-frame transcript (<xref rid='F2' ref-type='fig'>figure 2</xref>).</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Quantitative PCR analysis showed 30% reduced expression in lymphoblast cells and 50% reduced expression in brain (<xref rid='F2' ref-type='fig'>figure 2</xref>).</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Western blot analysis detected only the normal-sized protein band with 45% reduced expression in lymphoblast cells and 34% in brain lysates, suggesting that no stable protein was produced from the mutant transcripts (<xref rid='F3' ref-type='fig'>figure 3</xref>).</s></p><p><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>In lymphoblast cells of patients carrying the in-frame deletion mutations, p.Asp167del and p.Glu643del (n = 5), <italic>TBK1</italic> transcript expression was not reduced.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Also, cDNA sequencing showed the presence of both alleles.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, we observed a significantly reduced protein level of 44% in the p.Glu643del carriers (<italic>p</italic> = 0.0017).</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the p.Asp167del carrier, protein expression was not altered (<xref rid='F3' ref-type='fig'>figure 3</xref>).</s></p><p><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The 5 missense mutations were scattered over the 4 functional domains (table e-1 and figure e-1).</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Three missense mutations—p.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Arg271Leu, p.His322Tyr, and p.Ile515Thr—were absent from 1,044 control individuals.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We observed p.Ala535Thr in 1 male control (age at inclusion 63 years), and p.Lys291Glu in a male control and a female control (age at inclusion 67 and 69 years).</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Two mutations, p.Arg271Leu and p.Ala535Thr, were predicted neutral, while the other 3 mutations received variable effects using 3 prediction algorithms.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Missense mutation carriers did not show reduced transcript and protein expression levels (figure e-2).</s></p></sec><sec id='s2-2'><title>DR158 family, segregation, and sharing of p.Glu643del.</title><p><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Six unrelated index patients carried the p.Glu643del mutation (<xref rid='T1' ref-type='table'>table 1</xref>), among them index patient III-8 of autosomal dominant FTD-ALS family DR158, containing 13 patients (<xref rid='T1' ref-type='table'>table 1</xref> and <xref rid='F1' ref-type='fig'>figure 1</xref>).</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Ten patients of family DR158 were diagnosed with a dementia syndrome, i.e., FTD (n = 4) or unspecified dementia (n = 6), while 2 patients had a diagnosis of ALS.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean onset age was 69.1 ± 7.7 years, with a mean disease duration of 6.4 ± 3.9 years.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The 5 patients with FTD or FTD-ALS presented with bvFTD (table e-2).</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Remarkably, memory loss and disorientation were present relatively early in the disease in most of the p.Glu643del mutation carriers (table e-2).</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, most of these patients also developed early behavioral problems.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> One patient with ALS (III-1) and 1 patient with FTD-ALS (III-8) presented with ALS with spinal onset (table e-2), both showing signs of motor neuron disease on EMG.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Analysis of all family members indicated that the disease segregated with the p.Glu643del mutation on a disease haplotype of minimal 7.5 Mb (<xref rid='F1' ref-type='fig'>figure 1</xref>).</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Seven mutation carriers were without symptoms at age ≥70 years, including obligate carrier II-5 and 2 children of II-5 who, at their last clinical evaluation, were 79, 81, and 82 years of age, respectively (<xref rid='F1' ref-type='fig'>figure 1</xref>).</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Given the frequent occurrence of psychiatric disease in family DR158, it cannot be excluded that symptoms of FTD were not recognized (table e-2).</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Carrier II-5 and one of her children with a current age of 81 years had repeated depression.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Carrier II-3 died at age 68 years and was diagnosed with schizophrenia.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> One of the asymptomatic children of patient II-1 had alcohol abuse and has a current age of 70 years.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Among the other 5 carriers of the p.Glu643del mutation and their relatives, we identified 2 distinct disease haplotypes that differed from that in DR158 (<xref rid='F1' ref-type='fig'>figure 1</xref> and table e-3).</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In family DR663, ALS patient II-1 and II-2 carried, besides the <italic>TBK1</italic> mutation, a <italic>C9orf72</italic> repeat expansion, as did the asymptomatic sib II-4 without the <italic>TBK1</italic> mutation, age 63 years (<xref rid='F1' ref-type='fig'>figure 1</xref>).</s></p></sec><sec id='s2-3'><title>Genotype–phenotype correlations.</title><p><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The mean onset age in the 11 patients carrying a LOF mutation (<xref rid='T1' ref-type='table'>table 1</xref>) was 59.6 ± 8.6 years.</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In 4 p.Glu643del carriers, excluding the 2 patients carrying a <italic>C9orf72</italic> repeat expansion, we calculated a mean onset age of 66.3 ± 3.9 years, which was significantly later (<italic>p</italic> = 0.04) than in the 5 patients with another LOF mutation, with a mean onset age of 57.4 ± 6.0 years.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> When we included all affected carriers of family DR158, the significance became stronger (<italic>p</italic> = 0.004).</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Also, the mean disease duration of 8.3 ± 1.8 years was significantly longer (<italic>p</italic> = 0.016) than the mean disease duration of 2.6 ± 2.2 years in the patients with another LOF mutation with an increasing effect if all DR158 patients were included (<italic>p</italic> = 0.002).</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Four of 5 FTD mutation carriers and the patient with FTD-ALS had behavioral variant FTD (bvFTD) (table e-2).</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The 3 patients with FTD with a p.Glu643del mutation expressed extrapyramidal symptoms, while the patients with FTD with another <italic>TBK1</italic> mutation did not (table e-2).</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In 1 patient with bvFTD (DR1120), muscular fasciculations were observed in 1 limb (table e-2).</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The proband of DR158 presented with spinal onset ALS; in the 3 other documented patients with ALS (DR663, DR1123, DR1124), the site of onset was bulbar (table e-2).</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Of 3 <italic>TBK1</italic> mutation carriers with ALS or FTD-ALS (DR158.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>III-8, DR1123, DR1124), we had EMG reports, while of 3 other patients with ALS (DR663, DR1044, DR1127), no detailed information was available.</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Based on a clinical examination, there was no cognitive evidence for FTD in the majority of ALS cases.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, in ALS patient DR1124 memory deficits and the impression of behavioral disinhibition were reported (table e-2), but we did not have sufficient information to determine if the criteria for possible FTLD were fulfilled.</s></p><p><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Neuropathologic brain examination of FTD patient DR189 (p.Gly272_Thr331del) showed mild neuronal loss of the frontal cortices.</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We found a moderate amount of TDP-43 and p62 neuronal cytoplasmic inclusions (NCI) and short dystrophic neurites but no intraneuronal intranuclear inclusions (<xref rid='F4' ref-type='fig'>figure 4, A, B, D, and E</xref>) compatible with a TDP type B proteinopathy.<sup><xref rid='R13' ref-type='bibr'>13</xref></sup></s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In ALS patient DR1124 (p.Ser518Leufs*32), pathologic signs of lower and upper motor neuron disease were apparent.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The TDP-43 positive NCI were mainly restricted to the hypoglossal nucleus and the ventral horn neurons of cervical and thoraco-lumbar spinal cord (<xref rid='F4' ref-type='fig'>figure 4, C, F</xref>).</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Staining with TBK1 showed variable cytoplasmic neuronal immunoreactivity.</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The Nissl substance of the neurons in the ventral horn of the spinal cord was stained.</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We did not observe differences between patients and controls (<xref rid='F4' ref-type='fig'>figure 4, G–L</xref>).</s></p><fig id='F4' position='float'><label>Figure 4</label><caption><title>TDP-43, p62, and TBK1 immunohistochemistry</title><p>Immunohistochemistry of frontal cortex (A, D, G) and hippocampus (B, E, H) of 1 patient with frontotemporal lobar degeneration with the p.Gly272_Thr331del mutation (DR189) and spinal cord (C, F, I) of 1 patient with amyotrophic lateral sclerosis (ALS) with the p.Ser518Leufs*32 mutation (DR1124) compared to a control individual without mutation (J–L). In frontotemporal dementia patient DR189, a mild neuronal loss of the frontal cortices and to a lesser extent of the temporal neocortex and the hippocampus was shown. A moderate amount of TDP-43 and p62 neuronal cytoplasmic inclusions (NCI) (arrows) and short dystrophic neurites, but no intraneuronal intranuclear inclusions, were found throughout all layers of the frontal (A, D) and temporal neocortices, in the dentate gyrus of the hippocampus (B, E), the parahippocampal transentorhinal cortex, the neostriatum, and the pallidum, but not in the cerebellum. In ALS patient DR1124, no explicit cortical abnormalities were present, but pathologic signs of lower and upper motor neuron disease were apparent. Severe demyelination of the pyramidal tract in mesencephalon, pons, medulla oblongata, and the entire spinal cord and severe neuronal loss in the hypoglossal nucleus, as well as in the ventral horns of the cervical and thoracic spinal cord, were observed. The TDP-43-positive (C) and p62-positive (F) NCI were mainly restricted to the hypoglossal nucleus and the ventral horn neurons of cervical and thoraco-lumbar spinal cord (arrows). Cytoplasmic TBK1 immunoreactivity (arrows) in cortical neurons of the frontal cortex (G, J), in the dentate gyrus of the hippocampus (H, K), and in the cervical ventral horn neurons (I, L) showed no differences between patients and controls. The TDP-43-positive inclusions were not stained with TBK1.</p></caption><graphic xlink:href='NEUROLOGY2015667717FF4'></graphic></fig></sec></sec><sec sec-type='discussion' id='s3'><title>DISCUSSION</title><p><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>The overall <italic>TBK1</italic> LOF mutation frequency is 1.7% (11/629), with 1.1% (5/460) in FTD, 4.5% (1/22) in FTD-ALS, and 3.4% (5/147) in ALS.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In patients with FTD, <italic>TBK1</italic> LOF mutations explained 3.2% of the unexplained familial FTD cases and were the third most common genetic cause after <italic>C9orf72</italic> and <italic>GRN</italic> mutations (figure e-3), consistent with the findings in a FTLD-TDP cohort.<sup><xref rid='R8' ref-type='bibr'>8</xref></sup></s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the ALS cohort, <italic>TBK1</italic> mutations were the second most common after <italic>C9orf72</italic> mutations (figure e-3).</s></p><p><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>All described LOF mutations, except 1, are different from those in the other published reports.</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The p.Glu643del mutation that was present in 6/629 (1%) unrelated Belgian patients was also found in 2/1,010 German patients with sporadic ALS.<sup><xref rid='R7' ref-type='bibr'>7</xref></sup></s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We showed segregation of the p.Glu643del mutation with disease.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The presence of 3 different disease haplotypes of at least 3 Mb among the p.Glu643del carriers might be explained by a mutation hotspot due to a repetitive (GAA)<sub>3</sub> sequence encoding 3 Glu residues (codons 641–643) or because of an extreme distant common founder.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Expression studies in lymphoblast cells and in brain of 3 LOF mutation carriers confirmed the loss of transcript and of protein leading to 50% reduced protein levels, as previously reported.<sup><xref rid='R7' ref-type='bibr'>7</xref>,<xref rid='R8' ref-type='bibr'>8</xref></sup></s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A novel finding is that the p.Glu643del mutation had no effect on transcript levels but resulted in a near 50% reduced protein expression in blood, possibly due to loss of protein stability.</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The p.Asp167del mutation and the missense mutations did not show reduced transcript or protein levels, but we cannot exclude their pathogenicity by mechanisms like reduced kinase activity or hampered protein dimerization.</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> TBK1 has a 4-domain structure with an N-terminal kinase domain (KD), a ubiquitin-like domain, an α-helical scaffold dimerization domain, and a C-terminal domain<sup><xref rid='R14' ref-type='bibr'>14</xref></sup> (figure e-1).</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The correct interplay among these domains is essential for proper kinase function.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> TBK1 is activated by trans-autophosphorylation of serine 172 (Ser172), for which homodimerization is required.<sup><xref rid='R15' ref-type='bibr'>15</xref>,<xref rid='R16' ref-type='bibr'>16</xref></sup></s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Ser172 is located in a kinase activation loop of the KD starting at the conserved DFG motif (residues 157–159) and extending to residue 198.<sup><xref rid='R15' ref-type='bibr'>15</xref></sup></s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Interestingly, the p.Asp167del mutation is located in this activation loop and hence might hamper the conversion of TBK1 to the active state.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In other <italic>TBK1</italic> reports, some missense mutations were found to be pathogenic.<sup><xref rid='R7' ref-type='bibr'>7</xref>,<xref rid='R8' ref-type='bibr'>8</xref></sup></s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Since at least one of the used prediction algorithms predicted that some of our missense mutations are pathogenic, we expect that some might hamper proper protein functioning.</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Further experiments are necessary to confirm these predictions.</s></p><p><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Clinical heterogeneity among the <italic>TBK1</italic> mutation carriers was apparent since all different phenotypes of the FTD-ALS spectrum and a wide range in age at onset and disease duration were present, comparable to what was observed in <italic>C9orf72</italic> expansion carriers.<sup><xref rid='R17' ref-type='bibr'>17</xref></sup></s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, remarkably, 5 of 6 FTD or FTD-ALS index patients with a <italic>TBK1</italic> mutation presented with bvFTD.</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The later onset age and longer disease duration associated with the p.Glu643del mutation suggested that this mutation has a milder pathogenic effect.</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Since amnestic deficits and orientation problems were apparent early in the disease process, it might be interesting to screen <italic>TBK1</italic> in patients with clinically diagnosed AD, also since in another study 2 of 4 patients with FTLD-TDP with a <italic>TBK1</italic> mutation presented with clinical AD.<sup><xref rid='R8' ref-type='bibr'>8</xref></sup></s><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In ALS family DR663, we found both the <italic>TBK1</italic> p.Glu643del mutation and a <italic>C9orf72</italic> repeat expansion (&gt;80 repeat units) segregating with disease.</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The 2 sibs who carried both mutations had a remarkably younger onset age (41 and 51 years) and a shorter disease duration (&lt;1 and 2 years) compared to the other p.Glu643del mutation carriers.</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Also, one other index patient of the ALS cohort, DR1044, carried both the <italic>TBK1</italic> p.Glu643del mutation and a <italic>C9orf72</italic> repeat expansion of only 59 repeat units.</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This patient had later onset age of 63 years, corroborating our recent findings that patients with a short repeat expansion (45–80 units) have a later age at onset compared to patients with a longer expansion.<sup><xref rid='R18' ref-type='bibr'>18</xref></sup></s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Further, the disease penetrance in p.Glu643del mutation is highly variable, with 7 carriers of family DR158 still unaffected at age ≥70 years, with 2 at age 81 and 82 years, nearly 2 SDs beyond the mean onset age.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The 7 unaffected carriers were not homozygous for the minor protective allele of <italic>TMEM106B</italic> rs1990622.<sup><xref rid='R19' ref-type='bibr'>19</xref></sup></s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The observed TDP-43 type B pathology in brain or spinal cord could be distinguished from that in patients with a <italic>C9orf72</italic> mutation by the absence of p62-positive inclusions containing dipeptide repeats.<sup><xref rid='R20' ref-type='bibr'>20</xref>,<xref rid='R21' ref-type='bibr'>21</xref></sup></s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This pathology was previously reported in 1 patient with FTD-ALS<sup><xref rid='R7' ref-type='bibr'>7</xref></sup> while another study reported FTLD-TDP type A in 3 mutation carriers.<sup><xref rid='R8' ref-type='bibr'>8</xref></sup></s></p><p><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The observation that <italic>TBK1</italic> mutations were present in a significant part of sporadic and late-onset patients is not uncommon in adult-onset neurodegenerative diseases because of reduced penetrance, similar to what is described for <italic>C9orf72</italic> mutations and to a lesser extent for <italic>GRN</italic> mutations.<sup><xref rid='R9' ref-type='bibr'>9</xref></sup></s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A relatively high de novo mutation rate may be another explanation, supported by the observation that the p.Glu643del mutation occurred on 3 different haplotype backgrounds.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Also, as proposed by others,<sup><xref rid='R8' ref-type='bibr'>8</xref></sup> more than 1 gene might be involved in some patients, as observed in family DR663 segregating both a <italic>TBK1</italic> and a <italic>C9orf72</italic> mutation.</s></p><p><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>TBK1 is an important serine/threonine kinase of the IKK family phosphorylating a wide range of substrates involved in several cellular processes, including innate immune response/inflammation,<sup><xref rid='R22' ref-type='bibr'>22</xref></sup> autophagy,<sup><xref rid='R23' ref-type='bibr'>23</xref>,<xref rid='R24' ref-type='bibr'>24</xref></sup> and cell proliferation.<sup><xref rid='R25' ref-type='bibr'>25</xref></sup></s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Substrates of TBK1 include optineurin (<italic>OPTN</italic>),<sup><xref rid='R26' ref-type='bibr'>26</xref>,<xref rid='R27' ref-type='bibr'>27</xref></sup> another gene with LOF mutations in ALS,<sup><xref rid='R28' ref-type='bibr'>28</xref></sup> and p62, a major component of pathologic depositions and showing mutations in FTLD and ALS.<sup><xref rid='R29' ref-type='bibr'>29</xref>,<xref rid='R30' ref-type='bibr'>30</xref></sup></s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> p62 and OPTN are 2 autophagic adapters controlling protein degradation by selective autophagy.<sup><xref rid='R31' ref-type='bibr'>31</xref>,<xref rid='R32' ref-type='bibr'>32</xref></sup></s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, TBK1 targets the VPS37C protein of the endosomal sorting complex required for transport-I,<sup><xref rid='R33' ref-type='bibr'>33</xref></sup> thereby regulating the vesicular retroviral budding system, which is also involved in neurodegeneration, e.g., CHMP2B.<sup><xref rid='R34' ref-type='bibr'>34</xref></sup></s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A dysfunctional vesicular transport system might in turn induce autophagy defects.<sup><xref rid='R35' ref-type='bibr'>35</xref></sup></s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> As other FTD/ALS genes, including VCP,<sup><xref rid='R36' ref-type='bibr'>36</xref></sup> are also involved in autophagy, and since mutations in <italic>OPTN</italic> and <italic>TBK1</italic> are also involved in glaucoma,<sup><xref rid='R37' ref-type='bibr'>37</xref>,<xref rid='R38' ref-type='bibr'>38</xref></sup> our findings emphasize the major role of autophagic defects in neurodegeneration.<sup><xref rid='R39' ref-type='bibr'>39</xref></sup></s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Also, in the antiviral innate immune response both TBK1 and OPTN are involved through the NF-KB complex pathway.<sup><xref rid='R40' ref-type='bibr'>40</xref></sup></s></p><p><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In this study, we demonstrated that LOF mutations in <italic>TBK1</italic> are associated with FTD-ALS spectrum disorders in a Belgian clinical patient cohort, can segregate in families according to an autosomal dominant pattern, and are present in a significant part of sporadic cases.</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The identification of <italic>TBK1</italic> emphasizes the convergence of FTD and ALS in 1 continuum and will accelerate effective drug development.</s></p></sec><sec sec-type='supplementary-material'><title>Supplementary Material</title><supplementary-material content-type='local-data' id='PMC_1'><caption><title>Data Supplement</title></caption><media mime-subtype='html' mimetype='text' xlink:href='supp_85_24_2116__index.html'></media><media mime-subtype='msword' mimetype='application' xlink:role='associated-file' xlink:href='supp_WNL.0000000000002220_Appendix_e-1.docx'></media></supplementary-material><supplementary-material content-type='local-data' id='PMC_2'><caption><title>Coinvestigators</title></caption><media mime-subtype='html' mimetype='text' xlink:href='supp_85_24_2116_v2_index.html'></media><media mime-subtype='msword' mimetype='application' xlink:role='associated-file' xlink:href='supp_WNL.0000000000002220_Coinvestigators.docx'></media></supplementary-material></sec></body><back><fn-group><fn fn-type='supplementary-material'><p>Supplemental data at <ext-link ext-link-type='uri' xlink:href='http://neurology.org/lookup/doi/10.1212/WNL.0000000000002220'>Neurology.org</ext-link></p></fn></fn-group><ack><title>ACKNOWLEDGMENT</title><p>The authors thank the neurologists Marie-Claire De Poorter (AZ Oudenaarde), Frederik Clement (AZ Roeselare), and Marc Bruyland (AZ Glorieux Ronse) for their contribution to the clinical evaluation of patients, the personnel of the Genetic Service Facility of the VIB Department of Molecular Genetics (<ext-link ext-link-type='uri' xlink:href='http://www.vibgeneticservicefacility.be/'>http://www.vibgeneticservicefacility.be</ext-link>), and the Antwerp Biobank of the Institute Born-Bunge for their support.</p></ack><sec sec-type='contributions'><title>AUTHOR CONTRIBUTIONS</title><p content-type='contributions'>Ilse Gijselinck: literature search, figures, study design, genetic data collection, data analysis, data interpretation, writing. Sara Van Mossevelde: patient samples collection, clinical data collection, data analysis, data interpretation, writing. Julie van der Zee: patient data collection, genetic data collection, data analysis, data interpretation. Anne Sieben: patient samples collection, clinical data collection, neuropathology data collection, figures, data analysis, data interpretation, writing. Stéphanie Philtjens: genetic data collection, data analysis. Bavo Heeman: literature search, experimental data collection, data analysis, data interpretation. Sebastiaan Engelborghs: patient samples collection, clinical data collection, data analysis, data interpretation. Mathieu Vandenbulcke: patient samples collection, clinical data collection, data analysis, data interpretation. Greet De Baets: literature search, figures, protein structure data collection, data analysis, data interpretation. Veerle Bäumer: data collection, data analysis, data interpretation. Ivy Cuijt: genetic data collection, data analysis. Marleen Van den Broeck: genetic data collection, data analysis, data interpretation. Karin Peeters: patient samples collection, genealogy data collection, data analysis. Maria Mattheijssens: patient samples collection, genealogy data collection, data analysis. Frederic Rousseau: data analysis, data interpretation. Rik Vandenberghe: patient samples collection, clinical data collection, data analysis, data interpretation. Peter De Jonghe: patient samples collection, clinical data collection, data analysis, data interpretation. Patrick Cras: patient samples collection, clinical data collection, data analysis, data interpretation. Peter P. De Deyn: patient samples collection, clinical data collection, data analysis, data interpretation. Jean-Jacques Martin: patient samples collection, neuropathology data collection, data analysis, data interpretation, writing. Marc Cruts: literature search, study design, data interpretation, writing, study supervision. Christine Van Broeckhoven: literature search, figures, study design, genetic data collection, genealogy data collection, data analysis, data interpretation, writing, study supervision.</p></sec><sec sec-type='funding'><title>STUDY FUNDING</title><p content-type='funding'>The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The research was funded in part by <funding-source>the Belgian Science Policy Office Interuniversity program</funding-source>; <funding-source>the Flemish government-supported European Initiative on Centers of Excellence in Neurodegeneration</funding-source> (CoEN); <funding-source>the Flemish government-initiated Methusalem excellence program</funding-source>; <funding-source>the Flemish government-initiated Flanders Impulse Program on Networks for Dementia Research (VIND)</funding-source>; <funding-source>the Alzheimer Research Foundation (SAO-FRA)</funding-source>; <funding-source>the Medical Foundation Queen Elisabeth (QEMF)</funding-source>; <funding-source>the Research Foundation Flanders (FWO)</funding-source>; the Agency for Innovation by Science and Technology Flanders (IWT) and the University of Antwerp Research Fund, Belgium; and the MetLife Foundation Award for Medical Research to C.V.B. The FWO provided a PhD fellowship to S.P. and a postdoctoral fellowship to I.G. The Article Processing Charge was paid by the Flanders Impulse Program on Networks for Dementia Research (VIND).</p></sec><sec sec-type='disclosure'><title>DISCLOSURE</title><p content-type='disclosure'>The authors report no disclosures relevant to the manuscript. Go to <ext-link ext-link-type='uri' xlink:href='http://neurology.org/lookup/doi/10.1212/WNL.0000000000002220'>Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id='G1'>ALS</term><def><p>amyotrophic lateral sclerosis</p></def></def-item><def-item><term id='G2'>bvFTD</term><def><p>behavioral variant frontotemporal dementia</p></def></def-item><def-item><term id='G3'>FTD</term><def><p>frontotemporal dementia</p></def></def-item><def-item><term id='G4'>FTLD</term><def><p>frontotemporal lobar degeneration</p></def></def-item><def-item><term id='G5'>KD</term><def><p>kinase domain</p></def></def-item><def-item><term id='G6'>LOF</term><def><p>loss of function</p></def></def-item><def-item><term id='G7'>NCI</term><def><p>neuronal cytoplasmic inclusions</p></def></def-item><def-item><term id='G8'>Ser172</term><def><p>serine 172</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id='R1'><label>1.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lomen-Hoerth</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name></person-group><article-title>The overlap of amyotrophic lateral sclerosis and frontotemporal dementia</article-title>. <source>Neurology</source><year>2002</year>;<volume>59</volume>:<fpage>1077</fpage>–<lpage>1079</lpage>.<pub-id pub-id-type='pmid'>12370467</pub-id></mixed-citation></ref><ref id='R2'><label>2.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tsuji</surname><given-names>H</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Kametani</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Molecular analysis and biochemical classification of TDP-43 proteinopathy</article-title>. <source>Brain</source><year>2012</year>;<volume>135</volume>:<fpage>3380</fpage>–<lpage>3391</lpage>.<pub-id pub-id-type='pmid'>23035040</pub-id></mixed-citation></ref><ref id='R3'><label>3.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Dejesus-Hernandez</surname><given-names>M</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><etal></etal></person-group><article-title>Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS</article-title>. <source>Neuron</source><year>2011</year>;<volume>72</volume>:<fpage>245</fpage>–<lpage>256</lpage>.<pub-id pub-id-type='pmid'>21944778</pub-id></mixed-citation></ref><ref id='R4'><label>4.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Renton</surname><given-names>AE</given-names></name><name><surname>Majounie</surname><given-names>E</given-names></name><name><surname>Waite</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD</article-title>. <source>Neuron</source><year>2011</year>;<volume>72</volume>:<fpage>257</fpage>–<lpage>268</lpage>.<pub-id pub-id-type='pmid'>21944779</pub-id></mixed-citation></ref><ref id='R5'><label>5.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gijselinck</surname><given-names>I</given-names></name><name><surname>Van Langenhove</surname><given-names>T</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study</article-title>. <source>Lancet Neurol</source><year>2012</year>;<volume>11</volume>:<fpage>54</fpage>–<lpage>65</lpage>.<pub-id pub-id-type='pmid'>22154785</pub-id></mixed-citation></ref><ref id='R6'><label>6.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cirulli</surname><given-names>ET</given-names></name><name><surname>Lasseigne</surname><given-names>BN</given-names></name><name><surname>Petrovski</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways</article-title>. <source>Science</source><year>2015</year>;<volume>347</volume>:<fpage>1436</fpage>–<lpage>1441</lpage>.<pub-id pub-id-type='pmid'>25700176</pub-id></mixed-citation></ref><ref id='R7'><label>7.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Freischmidt</surname><given-names>A</given-names></name><name><surname>Wieland</surname><given-names>T</given-names></name><name><surname>Richter</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia</article-title>. <source>Nat Neurosci</source><year>2015</year>;<volume>18</volume>:<fpage>631</fpage>–<lpage>636</lpage>.<pub-id pub-id-type='pmid'>25803835</pub-id></mixed-citation></ref><ref id='R8'><label>8.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pottier</surname><given-names>C</given-names></name><name><surname>Bieniek</surname><given-names>KF</given-names></name><name><surname>Finch</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease</article-title>. <source>Acta Neuropathol</source><year>2015</year>;<volume>130</volume>:<fpage>77</fpage>–<lpage>92</lpage>.<pub-id pub-id-type='pmid'>25943890</pub-id></mixed-citation></ref><ref id='R9'><label>9.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Van Langenhove</surname><given-names>T</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><name><surname>Gijselinck</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort</article-title>. <source>JAMA Neurol</source><year>2013</year>;<volume>70</volume>:<fpage>365</fpage>–<lpage>373</lpage>.<pub-id pub-id-type='pmid'>23338682</pub-id></mixed-citation></ref><ref id='R10'><label>10.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>de Carvalho</surname><given-names>M</given-names></name><name><surname>Dengler</surname><given-names>R</given-names></name><name><surname>Eisen</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Electrodiagnostic criteria for diagnosis of ALS</article-title>. <source>Clin Neurophysiol</source><year>2008</year>;<volume>119</volume>:<fpage>497</fpage>–<lpage>503</lpage>.<pub-id pub-id-type='pmid'>18164242</pub-id></mixed-citation></ref><ref id='R11'><label>11.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Brooks</surname><given-names>BR</given-names></name><name><surname>Miller</surname><given-names>RG</given-names></name><name><surname>Swash</surname><given-names>M</given-names></name><name><surname>Munsat</surname><given-names>TL</given-names></name></person-group><article-title>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</article-title>. <source>Amyotroph Lateral Scler Other Motor Neuron Disord</source><year>2000</year>;<volume>1</volume>:<fpage>293</fpage>–<lpage>299</lpage>.<pub-id pub-id-type='pmid'>11464847</pub-id></mixed-citation></ref><ref id='R12'><label>12.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Neary</surname><given-names>D</given-names></name><name><surname>Snowden</surname><given-names>JS</given-names></name><name><surname>Gustafson</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria</article-title>. <source>Neurology</source><year>1998</year>;<volume>51</volume>:<fpage>1546</fpage>–<lpage>1554</lpage>.<pub-id pub-id-type='pmid'>9855500</pub-id></mixed-citation></ref><ref id='R13'><label>13.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Baborie</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>A harmonized classification system for FTLD-TDP pathology</article-title>. <source>Acta Neuropathol</source><year>2011</year>;<volume>122</volume>:<fpage>111</fpage>–<lpage>113</lpage>.<pub-id pub-id-type='pmid'>21644037</pub-id></mixed-citation></ref><ref id='R14'><label>14.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Lo</surname><given-names>YC</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><etal></etal></person-group><article-title>Crystal structure of inhibitor of kappaB kinase beta</article-title>. <source>Nature</source><year>2011</year>;<volume>472</volume>:<fpage>325</fpage>–<lpage>330</lpage>.<pub-id pub-id-type='pmid'>21423167</pub-id></mixed-citation></ref><ref id='R15'><label>15.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Larabi</surname><given-names>A</given-names></name><name><surname>Devos</surname><given-names>JM</given-names></name><name><surname>Ng</surname><given-names>SL</given-names></name><etal></etal></person-group><article-title>Crystal structure and mechanism of activation of TANK-binding kinase 1</article-title>. <source>Cell Rep</source><year>2013</year>;<volume>3</volume>:<fpage>734</fpage>–<lpage>746</lpage>.<pub-id pub-id-type='pmid'>23453971</pub-id></mixed-citation></ref><ref id='R16'><label>16.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Helgason</surname><given-names>E</given-names></name><name><surname>Phung</surname><given-names>QT</given-names></name><etal></etal></person-group><article-title>Molecular basis of tank-binding kinase 1 activation by transautophosphorylation</article-title>. <source>Proc Natl Acad Sci USA</source><year>2012</year>;<volume>109</volume>:<fpage>9378</fpage>–<lpage>9383</lpage>.<pub-id pub-id-type='pmid'>22619329</pub-id></mixed-citation></ref><ref id='R17'><label>17.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Gijselinck</surname><given-names>I</given-names></name><name><surname>Van Langenhove</surname><given-names>T</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><article-title>Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum</article-title>. <source>Trends Neurosci</source><year>2013</year>;<volume>36</volume>:<fpage>450</fpage>–<lpage>459</lpage>.<pub-id pub-id-type='pmid'>23746459</pub-id></mixed-citation></ref><ref id='R18'><label>18.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gijselinck</surname><given-names>I</given-names></name><name><surname>Van Mossevelde</surname><given-names>S</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter</article-title>. <source>Mol Psychiatry Epub</source><year>2015</year><comment>October 20</comment>.</mixed-citation></ref><ref id='R19'><label>19.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Sleiman</surname><given-names>PM</given-names></name><name><surname>Martinez-Lage</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions</article-title>. <source>Nat Genet</source><year>2010</year>;<volume>42</volume>:<fpage>234</fpage>–<lpage>239</lpage>.<pub-id pub-id-type='pmid'>20154673</pub-id></mixed-citation></ref><ref id='R20'><label>20.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ash</surname><given-names>PE</given-names></name><name><surname>Bieniek</surname><given-names>KF</given-names></name><name><surname>Gendron</surname><given-names>TF</given-names></name><etal></etal></person-group><article-title>Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS</article-title>. <source>Neuron</source><year>2013</year>;<volume>77</volume>:<fpage>639</fpage>–<lpage>646</lpage>.<pub-id pub-id-type='pmid'>23415312</pub-id></mixed-citation></ref><ref id='R21'><label>21.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Weng</surname><given-names>SM</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS</article-title>. <source>Science</source><year>2013</year>;<volume>339</volume>:<fpage>1335</fpage>–<lpage>1338</lpage>.<pub-id pub-id-type='pmid'>23393093</pub-id></mixed-citation></ref><ref id='R22'><label>22.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Clement</surname><given-names>JF</given-names></name><name><surname>Meloche</surname><given-names>S</given-names></name><name><surname>Servant</surname><given-names>MJ</given-names></name></person-group><article-title>The IKK-related kinases: from innate immunity to oncogenesis</article-title>. <source>Cell Res</source><year>2008</year>;<volume>18</volume>:<fpage>889</fpage>–<lpage>899</lpage>.<pub-id pub-id-type='pmid'>19160540</pub-id></mixed-citation></ref><ref id='R23'><label>23.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pilli</surname><given-names>M</given-names></name><name><surname>Arko-Mensah</surname><given-names>J</given-names></name><name><surname>Ponpuak</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation</article-title>. <source>Immunity</source><year>2012</year>;<volume>37</volume>:<fpage>223</fpage>–<lpage>234</lpage>.<pub-id pub-id-type='pmid'>22921120</pub-id></mixed-citation></ref><ref id='R24'><label>24.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Thurston</surname><given-names>TL</given-names></name><name><surname>Ryzhakov</surname><given-names>G</given-names></name><name><surname>Bloor</surname><given-names>S</given-names></name><name><surname>von Muhlinen</surname><given-names>N</given-names></name><name><surname>Randow</surname><given-names>F</given-names></name></person-group><article-title>The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria</article-title>. <source>Nat Immunol</source><year>2009</year>;<volume>10</volume>:<fpage>1215</fpage>–<lpage>1221</lpage>.<pub-id pub-id-type='pmid'>19820708</pub-id></mixed-citation></ref><ref id='R25'><label>25.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1</article-title>. <source>Nature</source><year>2009</year>;<volume>462</volume>:<fpage>108</fpage>–<lpage>112</lpage>.<pub-id pub-id-type='pmid'>19847166</pub-id></mixed-citation></ref><ref id='R26'><label>26.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Weidberg</surname><given-names>H</given-names></name><name><surname>Elazar</surname><given-names>Z</given-names></name></person-group><article-title>TBK1 mediates crosstalk between the innate immune response and autophagy</article-title>. <source>Sci Signal</source><year>2011</year>;<volume>4</volume>:<fpage>e39</fpage>.</mixed-citation></ref><ref id='R27'><label>27.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gleason</surname><given-names>CE</given-names></name><name><surname>Ordureau</surname><given-names>A</given-names></name><name><surname>Gourlay</surname><given-names>R</given-names></name><name><surname>Arthur</surname><given-names>JS</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><article-title>Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon beta</article-title>. <source>J Biol Chem</source><year>2011</year>;<volume>286</volume>:<fpage>35663</fpage>–<lpage>35674</lpage>.<pub-id pub-id-type='pmid'>21862579</pub-id></mixed-citation></ref><ref id='R28'><label>28.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Morino</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Mutations of optineurin in amyotrophic lateral sclerosis</article-title>. <source>Nature</source><year>2010</year>;<volume>465</volume>:<fpage>223</fpage>–<lpage>226</lpage>.<pub-id pub-id-type='pmid'>20428114</pub-id></mixed-citation></ref><ref id='R29'><label>29.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rubino</surname><given-names>E</given-names></name><name><surname>Rainero</surname><given-names>I</given-names></name><name><surname>Chio</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title>. <source>Neurology</source><year>2012</year>;<volume>79</volume>:<fpage>1556</fpage>–<lpage>1562</lpage>.<pub-id pub-id-type='pmid'>22972638</pub-id></mixed-citation></ref><ref id='R30'><label>30.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fecto</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Vemula</surname><given-names>SP</given-names></name><etal></etal></person-group><article-title>SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis</article-title>. <source>Arch Neurol</source><year>2011</year>;<volume>68</volume>:<fpage>1440</fpage>–<lpage>1446</lpage>.<pub-id pub-id-type='pmid'>22084127</pub-id></mixed-citation></ref><ref id='R31'><label>31.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Zheng</surname><given-names>YT</given-names></name><name><surname>Shahnazari</surname><given-names>S</given-names></name><name><surname>Brech</surname><given-names>A</given-names></name><name><surname>Lamark</surname><given-names>T</given-names></name><name><surname>Johansen</surname><given-names>T</given-names></name><name><surname>Brumell</surname><given-names>JH</given-names></name></person-group><article-title>The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway</article-title>. <source>J Immunol</source><year>2009</year>;<volume>183</volume>:<fpage>5909</fpage>–<lpage>5916</lpage>.<pub-id pub-id-type='pmid'>19812211</pub-id></mixed-citation></ref><ref id='R32'><label>32.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wild</surname><given-names>P</given-names></name><name><surname>Farhan</surname><given-names>H</given-names></name><name><surname>McEwan</surname><given-names>DG</given-names></name><etal></etal></person-group><article-title>Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth</article-title>. <source>Science</source><year>2011</year>;<volume>333</volume>:<fpage>228</fpage>–<lpage>233</lpage>.<pub-id pub-id-type='pmid'>21617041</pub-id></mixed-citation></ref><ref id='R33'><label>33.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Da</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding through targeting endosomal sorting complex required for transport-I</article-title>. <source>J Immunol</source><year>2011</year>;<volume>186</volume>:<fpage>3023</fpage>–<lpage>3030</lpage>.<pub-id pub-id-type='pmid'>21270402</pub-id></mixed-citation></ref><ref id='R34'><label>34.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Urwin</surname><given-names>H</given-names></name><name><surname>Authier</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations</article-title>. <source>Hum Mol Genet</source><year>2010</year>;<volume>19</volume>:<fpage>2228</fpage>–<lpage>2238</lpage>.<pub-id pub-id-type='pmid'>20223751</pub-id></mixed-citation></ref><ref id='R35'><label>35.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lee</surname><given-names>JA</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>FB</given-names></name></person-group><article-title>Autophagy defects contribute to neurodegeneration induced by dysfunctional ESCRT-III</article-title>. <source>Autophagy</source><year>2009</year>;<volume>5</volume>:<fpage>1070</fpage>–<lpage>1072</lpage>.<pub-id pub-id-type='pmid'>19738424</pub-id></mixed-citation></ref><ref id='R36'><label>36.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Watts</surname><given-names>GD</given-names></name><name><surname>Wymer</surname><given-names>J</given-names></name><name><surname>Kovach</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein</article-title>. <source>Nat Genet</source><year>2004</year>;<volume>36</volume>:<fpage>377</fpage>–<lpage>381</lpage>.<pub-id pub-id-type='pmid'>15034582</pub-id></mixed-citation></ref><ref id='R37'><label>37.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rezaie</surname><given-names>T</given-names></name><name><surname>Child</surname><given-names>A</given-names></name><name><surname>Hitchings</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Adult-onset primary open-angle glaucoma caused by mutations in optineurin</article-title>. <source>Science</source><year>2002</year>;<volume>295</volume>:<fpage>1077</fpage>–<lpage>1079</lpage>.<pub-id pub-id-type='pmid'>11834836</pub-id></mixed-citation></ref><ref id='R38'><label>38.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Robin</surname><given-names>AL</given-names></name><name><surname>Stone</surname><given-names>JL</given-names></name><etal></etal></person-group><article-title>Copy number variations on chromosome 12q14 in patients with normal tension glaucoma</article-title>. <source>Hum Mol Genet</source><year>2011</year>;<volume>20</volume>:<fpage>2482</fpage>–<lpage>2494</lpage>.<pub-id pub-id-type='pmid'>21447600</pub-id></mixed-citation></ref><ref id='R39'><label>39.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name><name><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><article-title>Autophagy fights disease through cellular self-digestion</article-title>. <source>Nature</source><year>2008</year>;<volume>451</volume>:<fpage>1069</fpage>–<lpage>1075</lpage>.<pub-id pub-id-type='pmid'>18305538</pub-id></mixed-citation></ref><ref id='R40'><label>40.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Savitsky</surname><given-names>D</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><article-title>Regulation of immunity and oncogenesis by the IRF transcription factor family</article-title>. <source>Cancer Immunol Immunother</source><year>2010</year>;<volume>59</volume>:<fpage>489</fpage>–<lpage>510</lpage>.<pub-id pub-id-type='pmid'>20049431</pub-id></mixed-citation></ref></ref-list></back></article></PAPER>